News
-
-
-
-
-
PRESS RELEASE
Melrose Ventures Announces Significant Stake in Hank Payments Corp and Takeover Bid Tender
Melrose Ventures Group, with largest stake in Hank Payments Corp, aims to acquire controlling equity to rebuild business and enhance share value, expressing concerns over management's recent actions -
PRESS RELEASE
Original-Research: SYZYGY GROUP (von GBC AG): Kaufen
Die SYZYGY GROUP verzeichnet einen leichten Umsatzrückgang in den ersten neun Monaten 2024, kann aber das operative Ergebnis verbessern. Das Management passt die Guidance für das Gesamtjahr 2024 an und erwartet eine seitwärtsgerichtete Umsatzentwicklung. Neue Wachstumsprognosen und ein aktualisiertes DCF-Bewertungsmodell führen zu einem neuen Kursziel von 6,60 €. GBC AG stuft die SYZYGY GROUP weiterhin mit 'Kaufen' ein -
PRESS RELEASE
MEDICLIN increases consolidated sales and operating result - Management Board confirms annual forecast for 2024
MEDICLIN AG increases consolidated sales by 2.0% to EUR 558.2 million in 9M 2024, with Group EBIT reaching EUR 34.5 million. Management Board confirms 2024 forecast amid stable performance -
PRESS RELEASE
Gladstone Capital Corporation Exits its Investment in Antenna Research Associates, Inc.
Gladstone Capital Corporation announces sale of equity interest and debt investment in Antenna Research Associates, Inc. Realizes significant gain on equity. ARA specializes in designing and manufacturing antennas and RF systems for military and civilian applications -
PRESS RELEASE
LQR House Inc. Reports 424.58% Year-Over-Year Revenue Growth in October 2024 Compared to October 2023
LQR House Inc. reports significant revenue growth in October 2024, with a 424.58% year-over-year increase. Strategic partnerships driving momentum. CEO emphasizes recurring revenue from marketing services -
PRESS RELEASE
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals announces acceptance of late-breaking abstract on crofelemer results for breast cancer patients in OnTarget trial, presented at SABCS 2024